Psoriasis pathophysiology and impact on life

Tariq Alharbi, Ali Alzahrani, Afaf Hakami, Adeeb Almohammadi, Abdullah Alsaadi, Norah Bin Magbel, Najd AlJuaid, Haneen Almasoudi, Taif Alruwaili, Sarah Alkhezzi


Psoriasis is a chronic skin disorder with various morphology, distribution, severity, and course of disease. The goal of the management is to control disease activity to a level that allows a sufficient quality of life with minimal toxicity from the treatment itself. Unfortunately, 25% of patients suffering from psoriasis experience major psychological distress. Its chronic nature with associated comorbidities has a negative impact on quality of life. We conducted this review using a comprehensive search of MEDLINE, PubMed and EMBASE from January 1996 to March 2017. The following search terms were used: psoriasis, pathogenesis of psoriasis, psoriasis management, quality of life in psoriasis patients. We tried to study the pathogenesis, and management of psoriasis, and understand its effect on the quality of life of patients. Due to the chronic nature and its obvious visibility on skin, many patients suffer from major psychological adverse effects. In majority of the time the health care providers fail to recognize or treat such comorbidities. Healthcare providers must be educated to provide patients with ways to tackle issues with multiple aspects, including psychological, in the management plan for better results.


Psoriasis, Chronic skin disorders, Pathogenesis of psoriasis, Management of psoriasis, Quality of life in psoriatic patients

Full Text:



Di Meglio P, Villanova F, Nestle F. O. Psoriasis. Cold Spring Harb Perspect Med. 2014: 4.

Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R. Quality of life in patients with psoriasis. Health Qual Life Outcomes. 2006;4:35.

Sarac G, Koca TT, Baglan T. A brief summary of clinical types of psoriasis. North Clin Istanb. 2016;3:79-82.

Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(2):18-25.

Guglielmetti A, Conlledo R, Bedoya J, Ianiszewski F, Correa J. Inverse psoriasis involving genital skin folds:successful therapy with dapsone. Dermatol Ther (Heidelb). 2012;2:15.

Singh RK, Lee KM, Ucmak D, Brodsky M, Atanelov Z, Farahnik B, et al. Erythrodermic psoriasis:pathophysiology and current treatment perspectives. Psoriasis (Auckl). 2016;6:93-104.

Benjegerdes KE, Hyde K, Kivelevitch D, Mansouri B. Pustular psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl). 2016;6:131-44.

Elahmed HH. Rapid improvement of palmoplantar psoriasis after cessation of smoking. Sultan Qaboos Univ Med J. 2013;13:188-9.

Miceli A, Schmieder GJ. Palmoplantar Psoriasis. 2018.

Schons KR, Knob CF, Murussi N, Beber AA, Neumaier W, Monticielo OA. Nail psoriasis:a review of the literature. An Bras Dermatol. 2014;89:312-7.

Krueger G, Ellis CN. Psoriasis--recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol. 2005;53:S94-100.

Afshar M, Martinez AD, Gallo RL, Hata TR. Induction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C:a review and analysis of 36 cases. J Eur Acad Dermatol Venereol. 2013;27:771-8.

Prieto-Perez R, Cabaleiro T, Dauden E, Ochoa D, Roman M, Abad-Santos F. Genetics of psoriasis and pharmacogenetics of biological drugs. Autoimmune Dis. 2013;2013:613086.

Clarke P. Psoriasis. Aust Fam Physician. 2011;40:468-73.

Martin DA, Towne JE, Kricorian G, Klekotka P, Gudjonsson JE, Krueger JG, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2013;133:17-26.

Dattola A, Del Duca E, Saraceno R, Gramiccia T, Bianchi L. Safety evaluation of apremilast for the treatment of psoriasis. Expert Opin Drug Saf. 2017;16:381-5.

Samarasekera EJ, Sawyer L, Wonderling D, Tucker R, Smith CH. Topical therapies for the treatment of plaque psoriasis: systematic review and network meta-analyses. Br J Dermatol. 2013;168:954-67.

Katz U, Shoenfeld Y, Zakin V, Sherer Y, Sukenik S. Scientific evidence of the therapeutic effects of dead sea treatments:a systematic review. Semin Arthritis Rheum. 2012;42:186-200.

Asztalos ML, Heller MM, Lee ES, Koo J. The impact of emollients on phototherapy: a review. J Am Acad Dermatol. 2013;68:817-24.

Halverstam CP, Lebwohl M. Nonstandard and off-label therapies for psoriasis. Clin Dermatol. 2008;26:546-53.

Boffa MJ, Chalmers RJ. Methotrexate for psoriasis. Clin Exp Dermatol. 1996;21:399-408.

Sivamani RK, Correa G, Ono Y, Bowen MP, Raychaudhuri SP, Maverakis E. Biological therapy of psoriasis. Indian J Dermatol. 2010;55:161-70.

Branisteanu DE, Voicu CM, Cretu A, Dimitriu A, Luca MC, Salavastru CM. Adverse reactions of biological therapy for psoriasis. Rev Med Chir Soc Med Nat Iasi. 2015;119:38-44.

Parrish L. Psoriasis: symptoms, treatments and its impact on quality of life. Br J Community Nurs. 2012;17:524-8.

Parisi R, Symmons DP, Griffiths CE, Ashcroft DM, Identification, Management of Psoriasis et al. Global epidemiology of psoriasis:a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377-85.